Press Releases

4 May 2019, SINGAPORE, CytoMed Therapeutics has been featured on The Straits Times! It is a great honour for us and we are excited to share with readers about our patented technologies and how we can make a difference in the field of cancer immunotherapy. CytoMed Therapeutics have three platforms which include donor blood γδT cell-based platform, iPSC-derived NK cells platform and iPSC-derived γδT cells platform, that can enable us to generate and proliferate the cancer “killer” cells and furthermore, to treat or even cure cancer in the future. We believe that we can help cancer patients with our advanced technology.

Find out Full Article on The Straits Times

More information with us at Facebook.

26 February 2019, KUALA LUMPUR, CytoMed Therapeutics signed the Memorandum of Understanding (MoU) with Clinical Research Malaysia (CRM) to further advance the medicine development, especially in the field of cell therapy and cancer research.

Incorporated in 2018, CytoMed Therapeutics is a spin-off from Singapore’s Agency for Science, Technology and Research (A*Star) and focuses on translating its patented technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers. We also engage in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics by using our proprietary technologies for our customers. 

For this particular collaboration, CytoMed Therapeutics will be partnering with IMR, which is being represented in this MOU by CRM to conduct an immunotherapeutic preclinical study initially. As the project progresses further, this will open up possibilities for future studies that go beyond the preclinical stage into translational studies and clinical trials. Mr Choo Chee Kong, the Director of CytoMed Therapeutics, said “This collaboration between CytoMed Therapeutics and CRM and Institute of Medical Research (IMR) will open doors for more cell therapy trials and treatment to come into Malaysia. Collaborating with IMR and CRM, we are looking forward to a first-in-human clinical trial for CAR- gamma delta-T cells in the world.” 

The signing of the MoU was witnessed by the Minister of Health, YB Datuk Seri Dr. Dzulkefly Ahmad, Secretary General of Health, YBhg. Dato’ Seri Dr. Chen Chaw Min, Director General of Health, YBhg. Datuk Dr. Noor Hisham Abdullah as well as Director of Institute of Medical Research, Dato Dr Fadzilah Kamaludin.

As a start-up company, we feel deeply honored and privileged to be the bridge to further strengthen the research partnership between Singapore and Malaysia. 

More information with us at Facebook.

Follow us for more updates